uric-acid-lowering drug
Phase 3Small molecule
uric-acid-lowering drug is one of 47 small molecule programs targeting Hyperuricemia. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1uric-acid-lowering drug
HHuashan Hospital
Phase 3
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Foscavir
CClinigen, Inc.
Preclinical
Valium
Akero TherapeuticsPreclinical
Clomid
FerringPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Reminyl
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment1 trial
Hyperuricemia1 trial
Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial
Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University·N/A·NCT04199325·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for uric-acid-lowering drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHuashan Hospital